Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $18.8 million.

  • Rhythm Pharmaceuticals' Share-based Compensation rose 7098.45% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 5372.49%. This contributed to the annual value of $39.7 million for FY2024, which is 2189.97% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Share-based Compensation stood at $18.8 million for Q3 2025, which was up 7098.45% from $15.9 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Share-based Compensation high stood at $18.8 million for Q3 2025, and its period low was $4.6 million during Q1 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' median Share-based Compensation value was $7.8 million (recorded in 2024), while the average stood at $8.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 1117.32% in 2022, then skyrocketed by 7956.63% in 2023.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Share-based Compensation stood at $4.7 million in 2021, then grew by 13.07% to $5.3 million in 2022, then skyrocketed by 64.06% to $8.7 million in 2023, then rose by 21.7% to $10.6 million in 2024, then skyrocketed by 78.19% to $18.8 million in 2025.
  • Its Share-based Compensation stands at $18.8 million for Q3 2025, versus $15.9 million for Q2 2025 and $12.9 million for Q1 2025.